Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Debt (2020 - 2023)

Mirum Pharmaceuticals (MIRM) has 4 years of Total Debt data on record, last reported at $1.1 million in Q1 2023.

  • For Q1 2023, Total Debt fell 45.39% year-over-year to $1.1 million; the TTM value through Mar 2023 reached $1.1 million, down 45.39%, while the annual FY2022 figure was $1.1 million, 45.39% down from the prior year.
  • Total Debt reached $1.1 million in Q1 2023 per MIRM's latest filing, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $2.2 million in Q2 2021 and bottomed at $847000.0 in Q3 2021.
  • Average Total Debt over 4 years is $1.5 million, with a median of $1.5 million recorded in 2020.
  • The widest YoY moves for Total Debt: up 114.62% in 2022, down 45.39% in 2022.
  • A 4-year view of Total Debt shows it stood at $1.3 million in 2020, then surged by 57.91% to $2.0 million in 2021, then plummeted by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Total Debt were $1.1 million in Q1 2023, $1.1 million in Q4 2022, and $1.8 million in Q3 2022.